Biotech’s Double-Edged Sword: Extraordinary Funding Run Contributes To Talent Crisis
Company Creation Outpaces Availability Of Experienced Candidates
Finding good leaders always has been hard, but record-breaking VC investment and IPOs, COVID-19 and diversity initiatives have compounded the growing problem.
You may also be interested in...
Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor
The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.
Tango Bypasses IPO Route With SPAC Merger
The cancer drug developer was planning to go public later this year, but its series B investor Boxer Capital proposed a merger with its special purpose acquisition corporation, BCTG Acquisition.
BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.